Loading…
SEER
Seer, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 81578P106
$1.80-3.23%Price as of Sep 23, 22:30 UTC · updated once a day, after the close
Key metrics
- Market cap
- $99.67M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.22
- ROE
- -26.45%
- Profit margin
- 0.00%
- Revenue growth
- -23.40%
- Beta
- 1.51
- 52-week high
- $2.41
- 52-week low
- $1.55
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -94.8% over 5Y.
today you would have $55.31▼ -94.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $1.83 | $2.31 | $1.94 | $5.80 | $22.81 | $56.14 | |
| P/S | 23.7x | 6.2x | — | 7.4x | 23.7x | 213.8x | 5071.5x |
| P/B | 0.8x | 0.4x | — | 0.3x | 0.8x | 2.8x | 7.7x |
| EPS | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MBOTMicrobot Medical Inc. | $1.48 | — | 1.4x | — | -32.91% | $99.4M |
| PARKPark Dental Partners, Inc. | $20.85 | — | 3.3x | — | -24.16% | $99.15M |
| YARWYarrow Bioscience, Inc. | $37.00 | — | — | — | — | $98.78M |
| VRCAVerrica Pharmaceuticals Inc. | $5.69 |
About the company
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
- 124
- Redwood City, United States
Company description provided by Yahoo Finance.